Q-omics provides the consensus-scored ANXA8 profile across patient tissues and cancer cell-line models. ANXA8 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ANXA8 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, ANXA8 RNA expression shows 12,566 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, LUAD, and ESCA as cancer lineages where ANXA8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANXA8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANXA8 survival associations across molecular data types. ANXA8 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANXA8 RNA expression–survival associations across cancer types. High ANXA8 expression shows unfavorable associations in KIRC, SCLC, HNSC, KIRP and PAAD, but favorable associations in MESO. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ANXA8 RNA expression.
This table summarizes ANXA8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in BRCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ANXA8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANXA8 shows lower tumor expression in LUAD, BRCA and LIHC and higher tumor expression in LUSC, HNSC and THCA. The LUAD box plot shows higher ANXA8 RNA expression in normal versus tumor tissue (log2 FC = −1.567, t-test p < 0.001).
This table shows molecular features associated with ANXA8 in patient tissues and cancer cell lines. In patient samples, ANXA8 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, ANXA8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BREAST.
